SEC Filing Analysis: Werewolf Therapeutics, Inc. (HOWL)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director made multiple small, indirect sales totaling $88,587 under a pre-established Rule 10b5-1 trading plan.
• Market Impact: The transaction is minor relative to the company's market capitalization and, being pre-planned, is unlikely to have a significant market impact.

Company Information

Field	Value
Company	Werewolf Therapeutics, Inc.
Ticker Symbol	HOWL
CIK	0001785530
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	EVNIN LUKE
CIK	0001134657
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-10 to 2025-12-12
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	82,971 (Aggregated)
Price Per Share	~$1.07 (Weighted Average)
Total Value	$88,586.51
Shares Owned After	2,890,128
Ownership Type	I (Indirect)

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$88,586.51
% of Market Cap	0.22%
Shares Transacted	82,971
% of Shares Outstanding	Not Available
Post-Transaction Ownership	2,890,128 shares
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $88.6k sale represents approximately 0.22% of the company's $40 million market capitalization. This is not a material amount.
• Ownership Concentration: The insider continues to hold a substantial indirect position of over 2.89 million shares through various funds. The sale constituted a very small fraction (~2.8%) of the insider's total reported holdings.
• Transaction Significance: The transaction's significance is low. The value is small relative to the company's market cap, and the sale was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, non-public information.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sales are minor in value and were executed under a pre-arranged 10b5-1 trading plan, which removes the element of spontaneous insider decision-making. The market typically discounts such transactions.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction size is too small to significantly impact trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by directors are common for portfolio management and do not typically signal a change in outlook for the company.

Additional Context

Special Circumstances

• 10b5-1 Plan: As disclosed in Footnote 1, these sales were made pursuant to a Rule 10b5-1 trading plan dated September 24, 2025. This allows insiders to sell a predetermined number of shares at a predetermined time.
• Indirect Ownership: The shares are held indirectly through several investment funds managed by entities where the reporting person is a managing member or director.